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Abstract
The role of Th17 responses in airway remodeling in asthma is currently unknown. We 
demonstrate that both parenteral and mucosal allergen sensitization followed by allergen 
inhalation leads to Th17-biased lung immune responses. Unlike Th17 cells generated in vitro, lung 
Th17 cells did not produce TNF-α or IL-22. Eosinophilia predominated in acute inflammation 
while neutrophilia and IL-17 increased in chronic disease. Allergen-induced tolerance involved 
Foxp3, Helios and GARP expressing regulatory T cells (Treg) and IL-10/IFN-γ priming. This 
Treg phenotype was altered in inflamed lungs and abrogated by inhalation of IL-17. Using Th17-
deficient mice with genetic disruption of gp130 in T cells, we showed that Th17 cells induce 
airway remodeling independent of the Th2 response. All-trans retinoic acid administration 
ameliorated Th17-mediated disease and increased Treg activity, while dexamethasone inhibited 
eosinophilia but not neutrophilia and enhanced Th17 development in vitro. Targeting the Th17/
Treg axis might therefore be therapeutic in neutrophilic and glucocorticoid-refractory asthma.
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Introduction
The key pathological features of asthma are airway hyperreactivity and remodeling, both of 
which are generally attributed to activities of allergen-driven Th2 cells and associated 
allergic inflammation. Based on animal models of acute and chronic allergen exposure, 
airway remodeling has been mainly associated with chronic lung inflammation while 
hyperreactivity is most prominent during acute phases of the disease. This suggests 
prolonged exposure of lung tissue to products of Th2 cells (e.g. IL-131, eosinophils2 or 
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TGF-ß3 leads to gradual remodeling of the tissue and decreased baseline lung function. 
However, recent studies in infants and young children have shown that remodeling is 
apparent at the earliest stages of asthma development, suggesting both features develop in 
parallel4.
Asthmatic inflammation is primarily driven by allergen-specific CD4 T cells which recruit a 
complex network of innate immune cells into the airways. CD4 T cells can differentiate 
along 4 distinct pathways after antigen exposure, directed by T-bet (Th1), GATA-3 (Th2), 
RORγt (Th17) or Foxp3 (Treg) transcription factors. Th17 cytokines have been implicated 
in the immunopathology of both asthma and chronic obstructive pulmonary disease5, 6. 
IL-17 (i.e. IL-17A) is a pro-inflammatory cytokine and IL-17-deficient mice develop 
reduced acute inflammatory responses in a classic mouse asthma model7. Th17 effectors 
recruit neutrophils into the airway since the IL-17 they produce induces secretion of IL-8, an 
important neutrophil-recruiting chemokine, from airway epithelial cells8 and smooth 
muscle9. Moreover, IL-17 stimulates release of IL-6 from human bronchial fibroblasts and 
G-CSF expression in bronchial epithelial cells, which stimulates neutrophil development and 
granulopoiesis10.
Adoptive transfer of in vitro-derived Th17 cells into allergen-challenged mice induces 
airway hyperreactivity and glucocorticoid-resistant inflammation11. On the other hand, 
IL-17 produced by γδ T cells promotes resolution of pre-established allergic airway 
inflammation, indicating distinct roles for IL-17 during sensitization and challenge phases12. 
Furthermore, skewing Th2 inflammation towards Th17 in an acute asthma model inhibited 
airway hyperreactivity13. However the role of Th17 cells in chronic asthmatic disease and 
airway remodeling is not known.
Airways harbour many microbes and allergens that do not result in persistent inflammation, 
and this tolerance is partly mediated by regulatory T cells (Treg). Th17 cells are closely 
related to the Foxp3+ Treg lineage. Although the majority of Foxp3+ Treg are thymically 
generated, Foxp3 Treg can be peripherally induced by TGF-ß and IL-2. Conversely, TGF-ß 
in the presence of IL-6 directs Th17 development. Expression of transcription factor Helios 
has been proposed as a marker for natural, thymic Treg, with low Helios expression in 
induced Treg14. Since the balance between Treg and Th17 responses may be controlled by 
IL-6, the IL-6 pathway represents a potential therapeutic target in inflammatory disease15. 
Here we characterized Th17 responses in acute and chronic airway inflammation triggered 
by parenteral or mucosal sensitization and suggest that naturally induced lung Th17 cells 
have a different phenotype from in vitro polarized cells. We tested experimental disruption 
of the Th17 response using all-trans retinoic acid (ATRA) treatment or genetic deletion of 
IL-6R signaling in T cells. Our data establish an important role for Th17 cells in airway 
remodeling and chronic neutrophilia, independent of allergic inflammation. Targeting the 
Th17 pathway in neutrophilic asthma is therefore of potential therapeutic benefit.
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Results
Primary T cell responses to inhaled allergen induce a mixed Th17/Th2/Treg phenotype
We first examined primary T cell responses to inhaled allergen to characterize responses 
primed via the lung mucosa. This avoided effects of artificial adjuvants on the response. 
TCR-transgenic OT-2 CD4 cells (OVA-specific) were labeled with CFSE and transferred 
into naive recipients given OVA allergen alone intranasally (i.n.; Fig 1A). Within 3 days 
OT-2 cells were present in mediastinal LN but not lung tissue and had undergone extensive 
clonal expansion, as demonstrated by CFSE dilution. After 4-6 divisions, some cells had 
developed into Th17 (IL-17+) and Th2 (IL-4+) effectors but none were Th1-like. This 
contrasts with in vitro characteristics of OT-2 cells, which have a strong Th1 bias (see Fig 
7A). Since allergen alone given i.n. is known to induce tolerance, we performed the same 
analysis with addition of the mucosal adjuvant TNF-α to the allergen, which is known to 
induce allergic sensitization16. Primary responses were enhanced (Fig 1B) in terms of both 
numbers of divisions and proportions of cytokine-producing cells. We also determined 
whether Treg cells present in OT-2 mice responded to i.n. allergen priming. Foxp3+ cells 
expanded to the same extent as Foxp3− CD4 cells, and their division was also enhanced by 
the mucosal adjuvant (Fig 1B).
Acute allergic airway inflammation is dominated by Th17 cells with a phenotype distinct 
from in vitro-generated Th17
The Th17-priming environment of the lung was confirmed in B6 mice sensitized with OVA/
alum and challenged acutely with OVA, the protocol most frequently used as an 
experimental asthma model (Figs 1C-G). T cells infiltrating the airways contained twice as 
many IL-17+ CD4 cells as IL-4+ Th2 cells (Fig 1C), and this Th17 predominance was more 
pronounced in lung CD4 cells (Fig 1D). OVA/alum sensitized animals showed no increase 
in CD4 cells producing Th1 cytokines or IL-22. Surface expression of the Th17 marker 
CCR6 and intracellular staining for the Th17 transcription factor RORγt were both increased 
on lung CD4 T cells (Fig 1E). Furthermore, significant increases in IL-17A, as well as the 
Th2 cytokine IL-13, were detected in bronchoalveolar lavage (BAL) fluids from mice with 
acute allergic inflammation, and the Th17-promoting cytokine IL-23 was also increased (Fig 
1F). Stimulation of lung cells with OVA+anti-CD28 in vitro also induced IL-17A 
production in lung CD4 cells, suggesting that the Th17 cells were allergen specific or at 
least dependent on allergen priming (Fig 1G). Lung Th17 cells clearly did not stain for TNF-
α, unlike in vitro generated IL-17+ cells (Fig 1H) which were nearly all TNF-α+ despite 
having downregulated IFN-γ production under Th17-polarizing conditions. There was also a 
difference, though not as dramatic, in IL-22 production - a substantial fraction of in vitro 
Th17 cells produced IL-22 while very few IL-22+ cells were found in the lung. CCR6 
expression did not correlate with Th17 development in vitro (not shown).
Chronic allergic airway inflammation is dominated by Th17 responses and neutrophilia 
irrespective of type of sensitization or route of exposure
Mice were sensitized with OVA combined with either the classic Th2-skewing adjuvant 
alum, Th17-promoting adjuvant CFA17 or Th1-skewing CASAC (combined adjuvant for 
synergistic activation of cellular immunity) 18, then examined for lung inflammation 
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induced by short-term or chronic mucosal allergen exposure. Surprisingly, Th17 was the 
predominant phenotype with all sensitization protocols at the acute stage (Fig 2A). Both 
alum and CFA sensitization induced mixed eosinophilia/neutrophilia. CASAC induced only 
neutrophilia with no Th1 cells apparent at the acute stage. After chronic challenge Th17 
cells and neutrophilia persisted while fewer eosinophils were present. Irrespective of mode 
of sensitization, we observed an increase in Th1 cells at the chronic stage. Thus the route 
and chronicity of allergen challenge were more important than the nature of initial 
sensitization in directing the response. However to ensure that our results were not 
influenced by systemic sensitization protocols we compared OVA/alum sensitization with 
mucosal sensitization via intranasal OVA+TNF-α treatment (Fig 2B-D). Mucosally 
sensitized mice also developed a Th17-dominated response with mixed eosinophilia/
neutrophilia. However eosinophilia was less pronounced and neutrophilia increased 
progressively as inflammation progressed through subchronic and chronic phases (Fig 2B). 
Proportions of IL-17+ cells decreased at the chronic stage with OVA/alum and increased 
with OVA/TNF-α sensitization (Fig 2C). IL-17A in BAL increased substantially at the 
chronic stage (Fig 2D) in mucosally but not parenterally sensitized mice. OVA/TNF-α 
resulted in significantly higher IL-17A and IFN-γ but lower IL-13 levels (Fig 2D) compared 
to OVA/alum. Airway remodeling was observed in both models, as indicated by 
peribronchiolar collagen deposition and increased airway smooth muscle (shown in 
supplementary Fig S1), and increased total lung collagen content (Fig 2E). H&E staining 
(Fig S1) revealed pronounced leukocytic inflammation around the airways at the chronic 
stage in both models.
Mucosal inflammation and tolerance to OVA both involve Treg recruitment but Treg from 
inflamed lungs have low Helios expression and proliferative responses
Since Th17 are closely related to the Foxp3 Treg lineage and RORγt and Foxp3 are 
reciprocally regulated, we investigated Treg responses in mice developing tolerance or acute 
lung inflammation to OVA challenge. It is well known that i.n. OVA challenge of 
unsensitized mice leads to tolerance. However compared to PBS challenge, OVA challenge 
of mice primed with alum only induced low level T cell infiltration of the airways (Fig 3A). 
Unlike in sensitized animals, there were no eosinophils or neutrophils recruited (Fig 3A). 
Suspecting that infiltrating T cells in tolerant mice were Treg, we found increased 
proportions of Foxp3+ CD4 T cells in the lung but not draining LN of both tolerant and 
sensitized animals (Fig 3B). Expression of GARP (Glycoprotein-A Repetitions 
Predominant), the Treg-associated activation marker19, was increased in both lung and LN 
(Fig 3C).
To determine whether the Treg were active in response to allergen, we CFSE-labeled lung 
and LN cells and cultured them in OVA for 4 days before CD4/Foxp3 staining. Cells from 
PBS-challenged mice failed to grow and Foxp3+ cells did not survive (Fig 3D upper panels). 
Cells from OVA-challenged unsensitized mice proliferated and a much higher proportion 
expressed Foxp3 after culture (Fig 3D,E&F). Interestingly, cells from inflamed lungs of 
sensitized mice contained high proportions of Foxp3+ CD4 cells but these Treg had not 
divided during culture in the presence of allergen. By contrast, Foxp3− CD4 cells from 
inflamed lung and both Treg and non-Treg from LN of either group divided extensively (Fig 
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3D,E&F). Since this suggested an impairment in Treg activity in the inflammatory 
environment of the lung, we also determined Helios expression in the same Treg before and 
after culture (Fig 3G&H). Helios expression within the Foxp3+ population was generally 
lower in lung cells than LN, but was increased during tolerance induction. By contrast CD4 
Treg from inflamed lung, but not LN, showed low Helios expression. The difference in 
Helios was most pronounced after culture in allergen (Fig 3H).
Respiratory tolerance involves priming for IL-10 and IFN-γ production in CD4 T cells
We measured the expression of IL-10 by intracellular staining of CD4 cells from OVA-
challenged tolerant or sensitized animals. IL-10 staining was not detectable directly ex vivo 
or in lung cells, but could be revealed after expansion of the draining LN cells in OVA for 4 
days (Fig 3I). There was little growth or IL-10 staining in control LN cultures, but CD4 cells 
from tolerant mice produced IL-10 and IFN-γ with a high proportion staining positive for 
both. These cytokines were reduced when animals were pre-sensitized. IL-10 could not be 
co-stained with Foxp3.
IL-17 abrogates respiratory tolerance and enhances epithelial permeability of airways to 
allergen
We asked whether IL-17 induced by allergen exposure could regulate activity of lung Treg 
and promote sensitization. Mice were treated i.n. with OVA alone, OVA + IL-17A, or OVA 
+ TNF-α as a positive control for sensitization. After re-challenge with OVA alone it was 
clear that IL-17 had induced recruitment of eosinophils and greatly increased T cell 
infiltration (Fig 4A). This was however much less inflammation than induced by TNF-α. 
Furthermore, the proliferative response of Foxp3+ CD4 Treg (as in Fig 3F) in tolerant mice 
was abrogated after IL-17 as well as TNF-α exposure (Fig 4B). Priming for IL-10 
production in draining LN CD4 cells was also significantly suppressed by IL-17 (Fig 4C). 
This abrogation of Treg activity could have been due to enhanced allergen uptake, since 
intranasal instillation of fluorescent-tagged OVA±IL-17 revealed that IL-17 promotes 
allergen uptake into lung tissue within 6 hours (Fig 4D). Uptake was by both CD11c+ and 
CD11c− cells, suggesting increased epithelial permeability after IL-17 exposure.
Th17-deficient mice display less airway remodeling after chronic allergen challenge
To determine the role of Th17 cells in airway remodeling we obtained CD4-
CreXgp130flox/flox mice20, here designated gp130−/−, which have a gp130 deficiency 
targeted to the T cell lineage. Since gp130 is the signaling component of the IL-6 receptor 
these mice have T cells unable to respond to IL-6R signaling. Animals with the gp130 
mutation but not the CD4-Cre recombinase transgene were used as controls and are referred 
to as wild-type (WT). We confirmed that CD4 cells from gp130−/− but not controls were 
deficient in Th17 development in vitro but not in Th1 or Th2 development (Fig 5A). We 
then compared groups of mice in which acute or chronic allergic airway inflammation had 
been induced, using the OVA/TNF-α mucosal sensitization model to maximize the chronic 
neutrophilic response. Lung eosinophilia was not significantly altered in the Th17-deficient 
strain at the acute or chronic stage, but neutrophilia was profoundly inhibited in Th17-
deficient mice (Fig 5B). Levels of BAL T cell infiltration were unchanged in gp130−/− 
animals at the acute stage but were less than WT mice by the chronic stage (Fig 5C). 
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Numbers of airway Th17 were reduced at both time points, while Th2 cells significantly 
increased in chronically challenged lungs from the gp130−/− strain. The shift from a Th17 to 
a Th2 response in gp130−/− was confirmed by detection of lower IL-l7 and higher IL-13 in 
BAL at both time points (Fig 5D). Although there was a trend for lower IFN-γ in gp130−/−, 
the Th1 response was negligible in these experiments. Most notably, at the chronic time 
point, the Th17-deficient animals had greatly reduced signs of airway remodeling as 
assessed by histology and lung collagen content (Fig 5E&F), despite the continued presence 
of eosinophils, Th2 cells and IL-13 in the airways of these mice.
Retinoic acid treatment alters the balance between Th17 and Treg activity
We determined whether all-trans retinoic acid (ATRA), the active form of vitamin A, could 
block Th17-associated pathology or increase Treg activity. We confirmed that ATRA 
specifically blocks Th17 differentiation in vitro, whilst not affecting Th2 or Th1 
development (Fig 6A). ATRA is known to enhance TGF-ß-induced Treg development in 
vitro21. Here we showed it also enhances growth/expansion of the natural Treg population 
(Fig 6B). CD4+CD25+ cell growth was enhanced by ATRA resulting in increased yields of 
Foxp3-staining CD4 cells, while expansion of Foxp3− cells in CD4+CD25− cultures was 
inhibited. The same effect was observed using the glucocorticoid dexamethasone (DEX, Fig 
6B). To determine effects of ATRA in vivo we induced chronic AAI by mucosal 
sensitization and then commenced i.p. ATRA dosing at 3 different time points (days 26, 35 
or 45); mice were killed on day 53. Only prolonged ATRA treatment (day 26 group) 
significantly inhibited T cell infiltration and neutrophilia (Fig 6C). By contrast ATRA 
enhanced eosinophilia, most significantly after a shorter period of treatment (Fig 6C). 
Prolonged ATRA treatment significantly reduced lung collagen content (Fig 6F) but its 
effect on Th17 cell numbers was not statistically significant and it had no effect on Th2 cells 
(Fig 6D). The proportion of Foxp3+ CD4 Treg cells in LN was temporarily increased after a 
week of ATRA treatment (day 45 group, Fig 6E). Although there was no increase in 
proportion of Foxp3+ Treg in lung tissue in any group, ATRA treatment did significantly 
increase expression of GARP on lung CD4 cells, indicating increased Treg activation. Thus 
ATRA treatment alters the balance of Th17 and Treg activity but its beneficial effects may 
be partially abrogated by enhanced eosinophilia. Finally, airway remodeling appeared to be 
improved by ATRA treatment from day 26 (Fig 6F), although there was no significant 
change in quantified smooth muscle α-actin (α-SMA; histological analysis is shown in 
supplementary Fig S2).
Dexamethasone enhances Th17 differentiation in vitro and fails to inhibit neutrophilia in 
vivo despite reduced T cell inflammation
Since Th17 cells have been associated with glucocorticoid-resistant airway inflammation11, 
we determined the effect of DEX on Th17 responses in vitro and in vivo. Addition of DEX 
to proliferating OT-2 CD4 cells in the presence of Th17-polarizing cytokines (TGF-ß, IL-6 
and IL-23) strongly enhanced Th17 differentiation (Fig 7A). Another drug with potent 
potentiating effects on Th17 development was UO126, an inhibitor of TCR-triggered 
MEK/ERK signaling (Fig 7A). Th17 cells induced by these drugs also expressed IL-22 
(supplementary Fig S3). Addition of both drugs induced the highest levels of Th17 
development and intracellular RORyt expression (Fig 7A lower panels). These data 
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indicated that glucocorticoid receptor and MAP kinase pathways are positive and negative 
regulators of Th17 development respectively. When we examined the effect of in vivo DEX 
treatment on acute and chronic airway disease initiated by mucosal sensitization, we found 
that prolonged DEX treatment inhibited lung Th17 recruitment and chronic eosinophilia 
(Figs 7B&C). However, neutrophilia was not inhibited by DEX. Short-term treatment of 
acute inflammation showed no significant inhibition by DEX. The increase in lung collagen 
content associated with airway remodeling was completely abrogated by DEX treatment 
(Fig 7D). Thus certain aspects of Th17/neutrophil-associated disease, which increase with 
prolonged allergen exposure, may be refractory to inhibition by glucocorticoids. We 
therefore measured production of further cytokines IL-17F, IL-22, IL-25 and IL-33 in this 
model. These cytokines were undetectable in BAL fluid but were secreted by draining LN 
cells after restimulation with OVA, with the exception of IL-17F which was undetectable 
(supplementary Fig S3). All cytokines were inhibited by in vivo DEX treatment. The distinct 
effect of DEX seen in vivo may be attributable to its ability to block expansion of OVA-
specific T cells in LN, as shown in Fig S3.
Discussion
Asthma has traditionally been viewed as an allergic disease mediated by Th2 airway 
infiltration and eosinophilia, but a more complex set of pathologies is now apparent. Poor 
understanding of asthma sub-phenotypes and over-reliance on a simplified model of acute 
experimental allergic asthma might explain the poor translation of new asthma therapies to 
the clinic. While the presence of the Th17 cell in asthma has been postulated for some time, 
our study is the first to establish a direct role for this pathway in airway remodeling and to 
examine immunomodulatory strategies for targeting Th17 cells in a chronic disease model. 
Th17 cells and IL-17 can play beneficial as well as detrimental roles in airway pathology. 
Predominance of the Th17 response in the lung may reflect that the Th17 phenotype is 
tailored to meet the needs of the respiratory mucosa, increasing immune surveillance while 
restricting tissue damage via curtailment of inflammation or cross-regulation of allergic 
responses12, 13. Nevertheless it is clear from our data that chronic Th17 inflammation 
contributes to airway remodeling and persistence of allergen sensitivity with increasing 
neutrophilia. Since IL-17 increases allergen transfer into lung tissue, allergen-driven Th17 
cells might also increase susceptibility of lung tissue to infection, resulting in asthma 
exacerbations 22 or accelerated tissue damage.
In humans, immune responses to inhaled aeroallergens develop in the lung and draining LN. 
Many animal models bypass this route by using i.p. injections of allergen in alum adjuvant. 
Some features of this model are inconsistent with human asthma, e.g airway eosinophils can 
reach 80%23, whereas in patients it is rarely greater than 5%24. The mixed Th17/Th2 
response we observed was apparent even in primary T cell responses in draining LN without 
adjuvant. Tolerance to inhaled OVA in naive mice did induce T cell activity and influx into 
the lung but this involved Treg and not T effectors. Foxp3+ Treg appear to be generated in 
respiratory LN in response to allergen, recruited to the lung and then further activated by 
allergen. We demonstrated priming for IL-10 and IFN-γ production during tolerance, both 
cytokines known to block allergic inflammation and/or Th17 responses25-27. We could not 
determine whether the allergen-induced Treg were derived from the natural or peripherally-
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induced Foxp3+ population. However since they expressed high Helios levels during 
tolerance and thymic Treg from OT-2 transgenic mice proliferated extensively upon 
exposure to inhaled OVA, it seems most likely they are derived from natural Treg.
Our novel observations on Treg activity and phenotype in inflamed lungs compared to 
tolerance may help in development of immunotherapeutic strategies. The inflammatory 
milieu of the lung appeared to block the ability of Treg to respond to allergen and this state 
of “paralysis” was associated with reduced Helios expression, a molecule recently 
associated with suppressive activity28. Although it is possible that the lack of response to 
OVA was due to a lack of OVA-specificity (i.e. inflamed lungs recruited large numbers of 
non-specific Treg), OVA-responsive Treg continued to be generated in LN. Perhaps a short-
lived inflammatory mediator present in lung tissue but not reaching LN was inhibiting local 
Treg activity. Reversing this hypothetical state of paralysis in local tissue Treg could 
potentially assist resolution of established disease.
The OVA/TNF mucosal sensitization model of chronic allergen exposure employed here 
resulted in less airway remodeling than OVA/alum but may be closer to the human situation 
and mimic the prominent neutrophilic response seen in some severe asthmatics29. This 
model recapitulates many clinical features of severe asthma, including closely associated 
IL-17 and neutrophil levels30, increasing Th17 markers with increasing severity of disease, 
increased expression of IL-23 and RORyt31, and early airway remodeling32. It therefore 
provides a potentially useful model for testing new asthma treatments, which can be 
introduced after initiation of remodeling. Use of OVA rather than house dust mite, which 
has natural adjuvanticity, allowed us to directly compare tolerance with inflammation in 
response to the same allergen, revealing that IL-17, like TNF-α, can abrogate tolerance. 
Activation of epithelium by IL-17 and increased epithelial permeability could expose lung 
tissue to more allergen-associated or other danger signals in the environment, blocking Treg 
activity. IL-17 also abrogated priming of CD4 cells for IL-10 and IFN-γ, associated with 
tolerance. Thus, as well as reciprocal expression of RORyt and Foxp3 in developing 
allergen-specific T cells, cross-regulation between IL-17 and IL-10 may underlie the 
inability of sensitized mice to resolve inflammation during persistent allergen exposure. This 
provides a rationale for therapeutic blockade of both IL-6 and IL-17.
IL-17 has a putative role in acute severe and chronic asthma33, 34. B6 mice demonstrate 
airway hyperreactivity during acute disease but this is much reduced in the chronic phase. 
We therefore did not study airway hyperreactivity in chronic disease but focussed on 
remodeling. We showed that IL-17 is increased alongside remodeling, and that allergen-
driven Th17 cells rather than other sources of IL-17 are capable of inducing remodeling. 
Although some murine DCs express CD4 and could potentially be affected by the mutation 
in gp130−/− mice, the profound defect we demonstrated in Th17 development is a more 
likely explanation for the lack of remodeling observed in this strain. Whether Th17 cells 
induce structural changes directly or via recruitment of neutrophils is not clear since there 
was a strong correlation between Th17 cells and neutrophilia.
Despite coexistence of Th17 and Th2 cells in inflamed tissues, there is some cross-
regulation between Th17 and other subsets, explaining beneficial effects of Th17 
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development on Th1/Th2-mediated disease. However models where plasticity between Th17 
and Th1/Th2 cells are prominent provides evidence for pathogenicity of Th17s. The late 
appearance of a Th1 response in the lung after chronic allergen challenge seen here (Figure 
2) has been observed previously35. It may reflect deviation from a Th17 to Th1 phenotype or 
be a consequence of remodeling and epithelial dysfunction, leading to a breakdown of 
mechanisms blocking Th1 responses in the lung. Interestingly it has been proposed that only 
fully mature Th17, after exposure to IL-23, produce Th1 cytokine TNF-α, and IL-2236. 
Since neither cytokine was detected in lung Th17 cells but both were produced by in vitro 
generated cells, in vitro derived Th17 used for adoptive transfer studies11 may be more 
differentiated and pathogenic than natural lung Th17. Clearly TNF-α production would have 
a potent sensitizing effect on the airway. Nevertheless, IL-17 alone was sufficient to 
abrogate respiratory tolerance, probably via activation of epithelial cells that strongly 
express IL-l7 receptor37.
Th17 deficient animals were skewed towards Th2 immunity compared to wild-type. 
Therefore a strong Th17 response to allergen may be beneficial in acute disease due to 
inhibition of more damaging Th2-mediated pathology, as proposed13. However failure to 
resolve acute Th17 inflammation can clearly lead to long-term tissue damage and 
remodeling. Since remodeling is such a prominent feature of human asthma, our data 
support the idea that Th17 pathways could be therapeutic targets in asthma. Natural Treg 
expansion was enhanced by ATRA, and in vivo ATRA treatment increases proportions of 
Treg in LN while enhancing their activation (reflected by GARP expression) in the lung. 
GARP (LRRC32) is an essential receptor for latent TGF-ß on the surface of active Treg19 
and is related to suppressive activity38. Treating mice with ATRA during the allergen 
challenge period ameliorated chronic disease despite exacerbating eosinophilia. This was not 
associated with an increase in Th2 cells and may have been due to ATRA directly enhancing 
eosinophil survival39. Our data indicate that IL-17 blockade could ameliorate or exacerbate 
disease dependent on the type of patient, and like retinoic acids, should be combined with a 
therapy that blocks Th2 inflammation.
Although DEX enhanced Th17 development in vitro, prolonged treatment with the drug in 
vivo inhibited Th17-mediated inflammation in chronic disease. This was probably due to the 
multiple effects of glucocorticoid on diverse cell types including DCs, which could have 
restricted expansion of allergen-specific T cells and their recruitment to the lung. However 
the in vitro experiments, in which excess allergen was provided to the cultures, would 
suggest activity of established Th17 effectors could be resistant to glucocorticoid. Chronic 
neutrophilia was uninhibited by DEX treatment, in contrast to eosinophilia. This could be 
due to resistance of Th17 cell activity to DEX inhibition or resistance of neutrophils to 
DEX-mediated apoptosis40. Although our data do not support the idea that glucocorticoid 
treatment could exacerbate Th17/neutrophilic components of asthma, they do suggest that 
other therapies may be indicated for treatment of severe/neutrophilic asthmatics. Most 
severe, treatment refractory asthma patients have mixed neutrophilia/eosinophilia while 
around 40% have only neutrophilia41. The latter group may benefit most from Th17-targeted 
therapies.
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Methods
Mice
All experiments were approved by our Institutional Animal Welfare Committee under UK 
Home Office Regulations. C57BL/6 (B6) mice (Harlan) were used at 4-8 weeks. OT-2 TCR 
transgenic mice, specific for OVA323-339/I-Ab and CD4-Cre+/−Xgpl30flox/flox mice provided 
by Dr Werner Müller (University of Manchester) were on a B6 background. Homozygous 
CD4-Cre+/+Xgp130flox/flox mice, with a deletion of the gp130 IL-6 receptor signaling 
component (Il6st, IL-6 signal transducer) specifically in T cells, were used as a Th17-
deficient strain20 and designated gp130−/−. Control groups in these experiments were CD4-
Cre−/−Xgp130flox/flox and designated wild type.
Assessment of primary allergen responses
MACS™-purified CD4 T cells from OT-2 LN + spleen cells were labeled with 5μM CFSE 
and transferred into the tail vein of B6 recipients given 50μg OVA ± lμg rmTNF-α in 50μl 
PBS i.n. After 3 days mediastinal LN cells were stimulated with PMA (l0ng/ml) + 
ionomycin (400ng/ml) + monensin (3μM) for 5 hours before intracellular cytokine staining.
Induction of acute and chronic allergic airway inflammation
For parenteral sensitization protocols, mice were sensitized i.p. with l0μg OVA in 0.2ml 
alum or complete Freund’s adjuvant or i.d. in CASAC as described42. Chronic challenge 
groups were immunized on days 0 and 12. Controls received PBS. For mucosal sensitization 
10μg OVA+1μg TNF-α was given i.n. on days 0 and 3. Acute challenge mice received 50μg 
OVA i.n. on days 7, 9-12, and were sacrificed day 13. Chronic groups received 50μg OVA 
i.n. daily between days 17 and 21, then 3 times a week from day 24 until day 53. All 
intranasal dosing was given in 50μl PBS/mouse under light inhaled anesthesia (isoflurane). 
OVA (Sigma, grade V) contained 0.4μg endotoxin per mg OVA protein.
Drug treatments
DEX (Sigma) was mixed with OVA and administered i.n. at 2μg/mouse. All-trans retinoic 
acid (ATRA, Sigma) in DMSO/olive oil was given i.p. at 100μg/mouse, controls received 
carrier alone. rmIL-17 was given at 0.5μg IL-17±50μg Alexa488-labelled OVA i.n.
Histopathology and immunostaining of lungs
Paraffin sections were stained with haematoxylin and eosin (H&E) or Picro-sirius red. For 
α-SMA staining deparaffinized sections were incubated with anti-α-SMA (Abcam, 1/25O) 
or control rabbit Ig revealed with VECTASTAIN® ABC kit (Vector Labs). Peri-bronchiolar 
collagen deposition and smooth muscle were quantitated using ImageScope image analysis 
software (Aperio Technologies) with virtual slides generated by a NanoZoomer 2.0-HT 
scanner, Hamamatsu Photonics. Circular lines were drawn around the outer and inner 
bronchiole of 5 bronchioles with a 150-200μm diameter at comparable sites for each slide, 
using ×400 magnification. The area of specific staining within the airway wall was 
calculated and divided by the length of the basement membrane for each bronchiole (μm2 
per μm).
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Collagen assay
Total lung collagen content was measured by Sircol kit (Biocolor Ltd).
Flow cytometry
Antibody staining (0.1μg/sample, eBioscience except anti-IL-22 (Poly5164, BioLegend), 
anti-IL-4 (BVD6-24G2, Caltag) and anti-CCR6 (29-2L17, BioLegend) was analyzed on a 
FACScalibur (BD). Inflammatory cells in BAL were identified as in43 with addition of anti-
Gr-1 to identify neutrophils (Gr-1+CD11c−CCR3−CD4−CD8−B220−). BAL T cells were 
separated with anti-CD3/28 Dynabeads and cultured with 3μM monensin for 5 hours. Total 
cell numbers were calculated by analysis of fixed sample volumes, validated with 
fluorescent beads. Lung T cells were stimulated with immobilized anti-CD3 (1μg/ml) + anti-
CD28 (1μg/ml) + monensin (3μM) or OVA (500μg/ml) + anti-CD28/monensin for 12 hours 
before intracellular cytokine staining as described44. Intracellular staining protocol for 
Foxp3 and Helios in CD25+ Treg was as described44.
BAL and LN supernatant ELISAs
ELISAs were performed on BAL fluid or supernatants from mediastinal LN cells cultured 
(2×l06/ml) for 72 hours with OVA (500μg/ml), as described45 using antibody pairs for 
IL-17A (R&D), IL-23 (eBioscience), IFN-γ (BD), IL-13 (Arcus), and eBioscience kits for 
IL-17F, IL-22, IL-25 and IL-33.
In vitro differentiation
Th17 cells were generated from naïve OT-2 CD4+ CD44lo T cells + splenic APC in 
XVIVO-15 + OVA323-339 (2μg/ml) + hTGFβ (3ng/ml) + IL-1ß (lOng/ml), IL-6 (20ng/ml) + 
IL-23 (10ng/ml) ± DEX (10nM) or UO126 (Calbiochem, 3μg/ml). Th1 cultures contained 
IL-12 (10ng/ml) and Th2 IL-4 (10ng/ml) + anti-IL-12/IFN-γ (2.5μg/ml).
Statistical analysis—Data are means ± SEM. Significance between groups was assessed 
using Student’s t tests except where SDs were significantly different, in which case Mann-
Whitney tests were used. In all figures * indicates P<0.05, **: P<0.01, ***: P<0.005.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Acute allergic airway inflammation consists of mixed Th17/Th2 responses
A&B: CFSE-labelled OT-2 CD4 cells were transferred into B6 mice and primary responses 
to inhaled OVA (A) or OVA±TNF-α (B) determined by flow cytometry of mediastinal LN 
after 3 days. Cells were stimulated with PMA+ionomycin before cytokine staining or stained 
for Foxp3. Data are from n=6 mice pooled from 3 experiments, statistical comparisons are to 
unstimulated cells (A) or OVA alone (B). C&D: Acute allergic airway inflammation was 
induced via OVA/alum sensitization or alum alone control and OVA i.n. challenge. BAL T 
cells (C) or lung T cells (D) were restimulated with anti-CD3/CD28 and cytokine staining in 
CD4 cells is shown (n=5, similar data were obtained in 3 independent experiments). E: 
Surface CCR6 and intracellular RORyt staining in CD4 cells as in D. F: Secreted cytokines 
in BAL supernatants from mice as in C. G&H: Lung Th17 cells are OVA-responsive and 
distinct in phenotype from in vitro-generated Th17: G shows IL-17 vs TNF-α staining in 
lung CD4 cells (as in D) stimulated with anti-CD3 or OVA + anti-CD28. H shows Th1 (top) 
and Th17 (bottom) cells generated in vitro from OT-2 CD4 cells and restimulated with 
PMA/ionomycin before IL-17, TNF-α and IFN-γ staining. Data are representative of 3 
experiments.
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Figure 2. Th17 responses persist during airway remodeling induced via parenteral or mucosal 
sensitization
A: Numbers of eosinophils, neutrophils and IL-17+ (Th17), IL-4+ (Th2) and IFN-γ+ (Th1) 
CD4 T cells in the BAL of mice after parenteral sensitization with Th1- (CASAC), Th2- 
(alum) or Th17-skewing (CFA) adjuvants. Acute (day 13) and chronic (day 53) stages of the 
response (as described in Methods) are shown. N=5, similar results were obtained in 2 
experiments. B-D: Mucosal sensitization with OVA+TNF-α induces an increasingly 
neutrophilic and IL-17-dominated response compared to parenteral OVA/alum sensitization. 
B shows eosinophilia & neutrophilia at acute (day 13) sub-chronic (day 33) and chronic 
stages of disease, C shows % Th1/2/17 cells in BAL CD4 cells. D: levels of cytokines in 
BAL supernatants. E total lung collagen assay. N=5, representative of 2 experiments. 
Histological analysis of airway remodeling is shown in supplementary figure S1.
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Figure 3. Respiratory tolerance involves lung Treg recruitment, but Treg in inflamed lung tissue 
are unresponsive
A: BAL numbers of inflammatory cells induced by 4 i.n. doses of OVA to unsensitized mice 
primed with alum only (OVA, i.e. tolerance) or parenterally sensitized mice primed with 
OVA/alum (OVA/alum, i.e. inflammation). Naïve controls received alum alone then PBS 
i.n. (PBS). N=5, representative of 3 experiments. B: %Foxp3+ Treg in CD4 cells of lung 
tissue and LN from mice as in A. C: Surface GARP expression on CD4 cells as in B. D-F: 
Cells as in B&C were CFSE-labelled and cultured for 4 days in OVA before Foxp3 staining. 
Proliferation of Foxp3+ CD4 cells was calculated as % divided within the Foxp3+ CD4+ 
population. D: representative flow cytometry profile, E: pooled % Foxp3+ data from 5 
experiments after 4 days culture, n=14. F: pooled % divided data within Foxp3+ CD4+ 
populations from 5 experiments. G&H: Helios expression expressed as MFI of staining 
within Foxp3+ CD4 cells from mice as in B, obtained directly ex vivo (G) or after 4 days 
expansion in OVA (H). I: IL-10 and IFN-γ staining in mediastinal LN as in D cultured for 4 
days in OVA and restimulated with PMA+ionomycin. CD4-gated events shown, mean
±SEM from 12 mice pooled from 4 experiments.
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Figure 4. IL-17 abrogates Treg-associated respiratory tolerance and enhances allergen uptake 
from airways to lung tissue
A: Numbers of inflammatory cells in BAL of mice treated i.n. with 2 doses of OVA (50@g) 
± IL-17 (0.5@g) or TNF-α (1μg), followed by 2 doses of OVA alone. Controls received 
PBS only. B: Treg activity in mice as in A, assessed by CFSE-labeling and culture for 4 
days in OVA prior to Foxp3 staining. Mean % divided ±SEM from 5 animals is shown. C: 
%IL-10 and IFN-γ staining within CD4 gate from mediastinal LN cultured for 4 days in 
OVA before PMA+ionomycin restimulation, n=5. D: Uptake of Alexa-488-labelled OVA 
onto lung tissue cells 6 hours after i.n. challenge of naive mice with 50@g OVA-Alexa488 ± 
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0.5μg IL-17. Histograms gated on CD11c+ DC/macrophages and CDllc− lung cells are 
shown, alongside MFIsCSEM from n=3 mice. Statistical comparisons to OVA only group 
are shown. Results are representative of 2 experiments.
Zhao et al. Page 19
Mucosal Immunol. Author manuscript; available in PMC 2014 November 17.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 5. Th17 deficiency caused by disrupted T cell IL-6 signaling leads to reduced chronic 
airway pathology
A: Cytokine staining in CD4 cells from gp130−/− (lower panels) or control (WT) mice 
cultured under Th1 (IL-12), Th17 (TGF-ß, IL-6/23, anti-IFN-γ) or Th2 (IL-4, anti-IL-12/
IFN-γ) polarizing conditions with anti-CD3+anti-CD28 for 5 days, representative of 3 
experiments. B-D: Altered airway inflammation in gp130−/− mice. Groups of gp130−/− or 
WT mice were mucosally sensitized with OVA/TNF-α and challenged with OVA until day 
13 (acute) or day 53 (chronic) time points (n=6, representative of 2 experiments). B: 
Infiltration of inflammatory cells in BAL; control animals received PBS only. C: Numbers 
of Th17, Th2 and Th1 CD4 cells in BAL, D: Cytokines in BAL supernatants. E&F: Th17 
deficiency abrogates airway remodeling. Chronically challenged gp130−/− or WT groups as 
in B were assessed by lung histology (E), with staining for collagen and α-SMA quantified 
in F. F also shows total lung collagen content. N=6, representative of 2 experiments.
Zhao et al. Page 20
Mucosal Immunol. Author manuscript; available in PMC 2014 November 17.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 6. ATRA treatment boosts Treg activity and inhibits chronic Th17/neutrophil-associated 
airway remodeling
A: Effect of ATRA on in vitro Th17, Th2 and Th1 development. OT-2 CD4 cells were 
cultured in polarizing conditions ± different ATRA concentrations for 6 days before 
washing and restimulation for cytokine staining. MeanMSEM from 3 experiments and 
expressed as % control (no ATRA). B: Effect of ATRA on CD4 Foxp3+ Treg expansion in 
vitro. CD25+ and CD25− CD4 cells were cultured with anti-CD3/28 + IL-2, ± ATRA, for 4 
days, stained for Foxp3 and numbers of Foxp3+ and Foxp3− cells in each culture counted by 
flow cytometry; representative of 3 experiments. C-G: Effect of in vivo ATRA treatment, 
commenced on day 26 (d26), day 35 (d35) or day 45 (d45) of chronic OVA/TNF-α protocol, 
on airway disease assessed on day 53. C shows eosinophil, neutrophil and T cell infiltration, 
without (OVA) or with ATRA treatments. N=5, representative of 2 experiments. D: 
Numbers of Th17, Th2 and Th1 cells in BAL. E: Treg marker expression in CD4 
populations from lung and LN cells. F: Total lung collagen assay. Histological analysis of 
airway remodeling is shown in supplementary Figure S2.
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Figure 7. Regulation of Th17 responses by glucocorticoid receptor and MEK signaling pathways
A: In vitro Th17 differentiation from OT-2 CD4 cells is enhanced by dexamethasone (DEX, 
10nM) and MEK inhibitor (UO126, 3μg/ml) – upper panel shows intracellular cytokine 
staining and lower panels show intracellular RORγt staining, means±SEM from 5 (upper 
panels) or 3 (lower panels) experiments. Statistical comparisons are to TGF-ß/IL-6/IL-23-
treated (upper) or control (lower). B: Effect of in vivo DEX treatment on acute (upper 
graphs) and chronic (lower graphs) airway inflammation induced by OVA+TNF-α mucosal 
sensitization followed by OVA (50μg) ± DEX (2μg) i.n. challenges. Numbers of BAL cells 
are shown (n=5). Similar data were obtained in 2 experiments. C: Numbers of BAL Th1, 
Th2 and Th17 cells as in B. Insufficient T cells were obtained from control mice for 
cytokine staining. D: Effect of DEX treatment on collagen deposition induced by OVA
+TNF-α mucosal sensitization and chronic OVA challenge. Control animals received PBS 
(n=5).
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